Wed, Oct 09, 2019 | By Jill Robinson, Inside Sales Manager
Early approvals of upcoming cell therapies have moved up manufacturing timelines for many firms in the biotech space. This blaze of approvals has been ignited by positive early clinical trial data...
Mon, Sep 16, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport
The human genome and diseases interact in mysterious ways. Along with external factors, these interactions can affect who gets an illness, how serious it gets, at what rate, how the patient...
Mon, Aug 26, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport
The advances in cell and gene therapy over the last few years have been nothing less than remarkable. The amount of resources being poured into their development is reflected in the large number...
Wed, Aug 21, 2019 | By Lindsay Belcher, Business Development Director - Northeast, Cryoport
Working for a company that supports cell and gene therapy industry, it’s always exciting to see new treatments finally go to market. Drug companies spend years trying to clear their new medicines...
Wed, Aug 14, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport
Cryoport was honored to be invited to speak at the CAR-T Summit in Shanghai, which gathered the world’s foremost experts on cell and gene therapy. While all presenters highlighted topics that were...
Mon, Jul 08, 2019 | By Kirk Randall, Senior Director, Business Development, Cryoport
We’re proud to provide global support for the first-ever commercial CART-T therapies, produced by our clients Kite (Gilead) and Novartis, as well as bluebird bio’s recently approved gene therapy....
Tue, Jun 25, 2019 | By Sue Blecman, Senior Director, Business Development, Cryoport
“By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment of the current pipeline and the clinical success rates of these...
Tue, Jun 11, 2019 | By Cryoport Team
This Monday, June 10 was a momentous day for our company: Members of the Cryoport team led the closing bell ceremony at Nasdaq, located in Times Square in New York City. Cryoport stock (CYRX)...
Wed, May 29, 2019 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
The regenerative medicine sector has grown significantly in the past few years, and it’s showing no signs of slowing down.
Wed, May 08, 2019 | By Cryoport Team
Cryoport is excited to be a Platinum Sponsor of the 2019 World Advanced Therapies and Regenerative Medicine Congress and Expo in London on May 15-17.
Tue, May 07, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport
There are mainly two types of cooling mechanisms used in the 2-8°C logistics process for biospecimen or drug substances, and they operate on different physics principles.
Wed, Apr 10, 2019 | By Cryoport Team
Technology often evolves faster than laws and regulations can keep up, and the field of regenerative medicine is evolving in the same way.
Fri, Apr 05, 2019 | By Soren H. Knudsen, Commercial Director, EMEA, Cryoport
The number of clinical trials is increasing: There are more than 275,000 registered on clinicaltrials.gov, a 26 percent increase from the year 2000.
Tue, Mar 19, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport
In 2016, Congress passed the 21st Century Cures Act. One of the more important aspects of the Act was to expedite the approval process for new drugs and medical devices. This Act has been a...
Mon, Mar 11, 2019 | By Lindsay Belcher, Business Development Director - Northeast, Cryoport
It’s happening…are you ready? As we are coming to the end of Q1 2019, the FDA recently finalized two guidance documents regarding Regenerative Medicine (as of Feb 15, 2019). There is no doubt...
Thu, Mar 07, 2019 | By Kirk Randall, Senior Director, Business Development, Cryoport
In choosing a logistics provider and important factor is to find someone who is carrier agnostic. So what does that mean? It means the solution provider is able to use, and track the performance...
Mon, Feb 25, 2019 | By Cryoport Team
Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the...
Wed, Feb 20, 2019 | By Sue Blecman, Senior Director, Business Development, Cryoport
We’re often asked by our clients what packaging and containment materials should be used to help prevent damage to their shipment contents.In reviewing shipper “packouts” with clients for upcoming...
Mon, Feb 11, 2019 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
On January 15th FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D, Director of the Center for Biologics Evaluation and Research released a public statement which outlined new...
Wed, Jan 23, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport
Evaporative cooling uses evaporation from a pocket of fluid to achieve cooling inside a shipping container, often targeting the 2-8°C range. Although it might be useful for situations with less...
Thu, Dec 20, 2018 | By Soren H. Knudsen, Commercial Director, EMEA, Cryoport
The short answer is: YES!If a specimen or biological material can transition through the freezing point — as happens when frozen in refrigerators and/or packed in dry ice — then holding it at...
Mon, Nov 19, 2018 | By Kirk Randall, Senior Director, Business Development, Cryoport
Dry vapor shipping dewars used for transport of critical temperature-controlled biomaterials and lifesaving materials, such CAR-T and other regenerative medicines, can be purchased and used by...
Thu, Nov 08, 2018 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
The global commercial approval of the first CAR-T therapies (Kymriah® and Yescarta®) has intensified the need for the clear and uninterrupted flow of data from before the patient is ever treated...
Wed, Oct 31, 2018 | By Sue Blecman, Senior Director, Business Development, Cryoport
The tedious process of vendor selection for Clinical Trials, Commercialization Planning and Launch in Regenerative Medicine can be daunting, let alone having to think about the Support necessary...
Wed, Oct 03, 2018 | By Nathan Dai, Senior Director, Business Development, Cryoport
With today’s research collaboration, supply chain distribution, clinical and commercial programs spanning across continents, it is essential for pharmaceutical or biotechnology companies to safely...
U.S. • The Netherlands • Singapore
Sales • +1 949.232.1900 | Support • +1 949.470.2300
